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1  Introduction
Human pluripotent stem cells (hPSCs) have opened fresh
avenues in modern medicine that have the potential to
revolutionise healthcare, particularly since the first deri-
vation of induced pluripotent stem cells (iPSCs) [1, 2].
Human embryonic stem cells (hESCs) and human-
induced pluripotent stem cells (hiPSCs) have the capaci-
ty to differentiate into all mature cell types, making them
attractive candidates for use as cell therapies [3]. More-
over, hPSCs also offer a unique, novel platform by which
to augment, and even redefine, current drug discovery
and drug screening programmes by the provision of a
human in vitro tool on which to perform efficacy and tox-
icity screens for novel chemical entities (NCEs) [4, 5].
 hiPSCs could also pave the way for personalised medicine
through the medium of responders versus non-responder
‘trial in a dish’ models [6]. 
hPSCs can provide a cornerstone of the regenerative
medicine industry via the provision of cell therapies for
diseases with unmet clinical needs. hiPSCs in particular
might provide a diagnostic tool capable of assuaging the
high late-phase failure rate of NCEs in clinical trials [7, 8].
The market for stem cell research products exceeded
$3bn at the end of 2013 (http://tinyurl.com/n26fe4z).
hPSCs for use as research tools are currently marketed at
$2000–$3000/vial [9]. However, the value of this market is
likely to be incremental when considered against hPSC-
derived cell therapies [10], which has the potential to tap
into a multi-billion dollar global market [11]. If hPSCs are
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to achieve their full clinical and commercial potential, sig-
nificant challenges must be overcome with regards to
current abilities to produce hPSC-derived cells at com-
mercially relevant scales.
At the forefront of current challenges to hPSC-derived
therapies is the production of cells at a relevant quantity
and quality to support their function. Details on the bio-
process techniques for hPSC therapies currently being
manufactured for preclinical and clinical trials or for use
as research tools are provided in Table 1. To date, hPSC-
derived products in development have mainly consisted
of retinal progenitor cells and pancreatic β-cells derived
from hESCs [12–15], or a variety of cell lineages such as
neurons, cardiomyocytes and hepatocytes derived from
hPSCs for use as research tools [16]. Promising results
have also been observed for cell therapies derived from
hiPSCs, such as retinal pigment epithelial cells [17]. 
Table 2 indicates that most products in clinical develop-
ment still depend on planar technologies. Traditional, pla-
nar technologies that offer reliable tools for laboratory-
based protocols are labour-intensive and do not lend
themselves to large scale, allogeneic processes [18]. Dose
sizes reported for hPSC-derived cell therapy products cur-
rently range from 5 × 104 cells for indications such as mac-
ular degeneration to 108 cells for diseases such as dia-
betes (Table 2). Furthermore, it has been estimated that
large doses, of around 109 cells, will be needed to treat
conditions such as myocardial infarction and liver disease
[19, 20]. Whilst this review focuses on process techniques
for the production of single-cell type populations, thera-
pies for certain disease types will necessitate transplan-
tation of a functional tissue-like structure. Novel, organoid
development techniques may therefore provide a method
of production of tissue-like structure representing a vari-
ety of different organs from small seed populations of
hPSCs. These have potential applications as either trans-
plantable therapies or research tools [21–24].
Planar technologies may struggle to satisfy the global
demand for hPSC-derived cell therapies requiring high
dose sizes [20, 25]. Furthermore, there is widespread use
of xenogeneic materials associated with traditional hPSC
technologies, preventing their use in the production of
clinical grade hPSC-derived cells. Differentiation strate-
gies have often represented idiosyncratic protocols that
have proven difficult to translate to robust bioprocess unit
operations [26]. Media costs associated with hPSC
processes are of further concern; many media supple-
ments render the products of current hPSC processes pro-
hibitively expensive for purpose. Additionally, studies
into the poorly understood interactions between hPSCs
and the microenvironment provided by media compo-
nents and cell anchorage materials are only now begin-
ning to take place; significant gaps exist in our knowledge
of how the design of such materials affects hPSC activity
[27].
Previous reviews in this field have discussed
advances in the large-scale expansion and bioreactor-
based culture of hPSCs (e.g. [25, 28–30]). Other studies
have focused upon the impact of the design of microcar-
riers and anchorage materials on hPSC bioprocessing
(e.g. [27, 31–33]). Herein, we aim to summarise key con-
siderations and methods that might be employed in order
to achieve cost-effective bioprocess design across a
range of manufacturing scales. Key process economic
metrics and drivers are outlined. A discussion of advance-
ments in robust, GMP-based expansion and directed dif-
ferentiation strategies is provided. Finally, a review of
recent innovations in integrated bioprocess design is pre-
sented.
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Table 1. Bioprocess development considerations for hPSC-derived
 products
Consideration Example Criteria
Operational Expansion yields (harvest densities)
performance Expansion folds 
Differentiation efficiencies
DSP yields
Purity
Resource utilisation
Scalability
Lot processing time
Economic Capital investment
Cost of goods (materials, labour, 
quality control and indirect)
Economies of scale – scale-up versus 
scale-out
Fresh versus frozen product 
transportation and storage
Process development costs
Supply chain replenishment
Product shelf-life
Reimbursement value
Quality control cGMP and cGTP standards
and regulatory Process robustness and reproducibility
compliance Process validation, acceptable ranges 
of operation
Product characterisation
Quality, consistency and source of raw 
materials
Automated versus manual processing
Safety Contamination and containment
Live human tissue handling
Patient safety – side-effects, risk of 
tumour formation
Flexibility Process changes
Manufacturing demand changes
Process bottlenecks
Process scalability
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2  Cell therapy bioprocess economics
When examining process options for hPSC manufacture,
it is important to consider not only the operational per-
formance but also the consequences on the economics,
quality, regulatory compliance, safety and flexibility.
These key considerations are summarised in Table 1. This
review pays particular attention to progress made on
improving the economic and operational feasibility of
hPSC bioprocessing.
Reimbursement pressures have resulted in an
increased awareness of the importance of estimating and
improving manufacturing costs for stem cell products. This
section discusses factors that influence two key cost met-
rics: fixed capital investment (FCI) and cost of goods (COG).
2.1  Capital investment
The FCI represents the cost to build a manufacturing
facility ready for start-up. It includes the cost of the build-
ing with the fixed (non-disposable) equipment, piping,
instrumentation and utilities installed. Estimates of facil-
ity costs are often made using factorial estimates. These
are well established for traditional stainless steel biophar-
maceutical facilities using the Lang Factor method [34],
which involves multiplying the total equipment purchase
cost by the ‘Lang factor’. At present, there are no pub-
lished studies that have determined an appropriate facto-
rial method for stem cell manufacturing facilities. The
Lang factor is usually derived based on the analysis of
costs of previous projects; as yet very few FCI bench-
marks have been published for stem cell manufacturing
facilities. Investment costs for stem cell facilities will also
be influenced by the degree of open versus closed pro-
cessing and the consequences on the cleanroom classifi-
cation required and whether automated or manual
process techniques are employed. Stem cell bioprocess-
ing is also dependent on disposable or single-use process
platforms such as T-flasks, CellStacks and single-use
bioreactors (SUBs). To this end, a Lang factor method
adapted for disposable-based biopharmaceutical facili-
ties is currently the best method available by which to
approximate the FCI associated with stem cell manufac-
turing [35]. Ongoing work at University College London is
focused upon developing a method for estimating FCI
that is specific to stem cell manufacturing facilities.
2.2  Cost of goods
The COG represents the cost to manufacture a stem cell
product and comprises direct (e.g. materials) and indirect
(e.g. maintenance) costs. Simaria et al. [20] summarise
key factors that influence COG values for stem cell prod-
ucts; these include process efficiencies (e.g. harvest den-
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Table 2. Technologies used for expansion and differentiation of hPSC-derived cell products used in clinical trials or as research tools
Company Indication Target cell type Dose size Cell expansiona) details Differentiation detailsa) Source
Cellectis Diabetes mellitus Insulin producing ND SUB: hollow fiber, SUB: hollow fiber, [12]
(type I) β-cells multicompartment multicompartment 
perfusion bioreactor perfusion bioreactor
Advanced Macular Retinal pigment 5 × 104 Planar: well-plates, Planar: well-plates [13]
Cell degeneration epithelial (RPE) MEF feeder layer, EB formation
Technology cells three passages
CellCure Macular RPE cells 2 × 104 Planar: well-plates Planar: well-plates, [14]
degeneration xeno-free media 8-wk process, serum-free 
conditions
Healios Macular RPE cells 5 × 104 Planar: plate-based custom Planar: plate-based custom [17]
degeneration designed automated designed automated 
process platform process platform
ViaCyte Diabetes mellitus Pancreatic β-cell 108 Planar: multi-layer cell Planar: plate-based aggregate [15]
(types I and II) precursors factories, 2-wk process, differentiation, 2-wk process, 
xeno-free media Xeno-free media
Geronb) Spinal cord Oligodendrocyte 2 × 106 Planar: matrigel coated Planar: T-flasks, 6-wk process, [111]
injuries progenitor cells T-flasks, 3- to 5-wk process growth factor-based protocol
Cellular hiPSC-derived Cardiomyocytes, N/A SUB: litre-scale, five SUB: litre-scale, chemically [16]
Dynamics cells for use as neurons, passages, Xeno-free media defined conditions
International research tools hepatocytes, 
endothelial cells
a) Technologies for expansion and differentiation operations are detailed alongside process durations and media where this information is available.
b) Geron’s GRNOPC1 therapy was withdrawn from trials but has been included in this table for comparison.
sities post-expansion, differentiation yields), technology
choices (e.g. planar vs. microcarrier-based SUBs), and
resources required and their unit costs (e.g. media, single-
use vessels and labour). Economies of scale are a relevant
factor as demand and lot size are varied as well as dose for
cell therapies and required cell population sizes for cells
as drug screening tools. Outputs are usually expressed as
COG per cell population for screening tools or COG per
dose for therapeutic applications.
Decision-support software can aid the design of cost-
effective bioprocesses. However, to date, few published
cost studies exist for stem cell bioprocessing. Commer-
cially available flowsheeting software packages have
been employed to cost stem cell process designs at fixed
scales [36]. Simaria et al. [20] and Hassan et al. [37] pres-
ent the development and application of decisional tools
that integrate models for mass balancing, equipment siz-
ing and bioprocess economics with optimisation algo-
rithms for allogeneic mesenchymal stem cell (MSC) pro-
duction. The tools were used to predict the most cost-
effective upstream and downstream technologies for
commercial MSC manufacture across a range of different
scales and doses. The analyses presented in these works
illustrate how such tools can be used to determine the
scale at which planar technologies cease to be cost-effec-
tive in contrast to microcarrier-based SUBs, when down-
stream processing bottlenecks occur, as well as future
required performance capabilities of promising technolo-
gies to close existing technology gaps and meet COG tar-
gets. This approach is being extended [38] to hPSC
processes, which typically have additional process steps
such as differentiation, so as to identify key economic
drivers for drug screening and therapeutic applications,
and predict technical innovations required to bridge the
gaps constraining widespread application of hPSCs.
In addition to considering the costs of stem cell bio-
processing alternatives, it is also useful to capture the
impact of uncertainties such as lot-to-lot variability and
contamination risks, particularly when manual processing
techniques are employed [39]. Stochastic modelling tech-
niques, such as the Monte Carlo simulation method, have
been used to evaluate process robustness under uncer-
tainty in the biopharmaceutical sector [35, 40, 41]. Sto-
chastic modelling has yet to be applied to iPSC process-
ing, but will form an important part of future work in order
to develop robust and cost-effective hPSC bioprocesses.
2.3  Process economic drivers
In order to achieve cost-effective bioprocesses for hPSCs,
efforts need to focus on increasing the overall productivi-
ty and/or decreasing the overall production costs. Hence,
critical process economic drivers for hPSC processes
include expansion and differentiation yields as well as the
cost of materials and labour. The remainder of this paper
therefore focuses on progress made on the expansion and
differentiation yields in planar and bioreactor technolo-
gies as well as the development of media and cell-anchor-
age materials for these unit operations.
3  hPSC bioprocessing strategies: Expansion
3.1  Planar culture systems for hPSC expansion
Until recently, planar hPSC culture platforms relied heav-
ily on the use of xenogeneic growth substrates and non-
human feeder layers, which risk contamination of hPSC-
derived products. Furthermore, feeder layers differential-
ly secrete signalling factors, resulting in poorly defined
culture conditions that are unsuitable for empirical study
of hPSC expansion [42]. The development of anchorage
materials comprising of a mixture of synthetic and/or
recombinant biological motifs have allowed hPSC culture
to progress away from the use of feeder layers [31].
The labour-intensive nature of T-flasks limits their
throughput and applicability to larger-scale processes [18,
25]. Systems that stack multiple culture chambers above
one another vertically have enabled greater cell yields
than traditional 2D culture methods at lower factory floor
footprints [43]. The Cell Factory (ThermoFisher Scientific,
Waltham, MA, USA), CellStack/ HyperStack (Corning,
New York, NY, USA) and Xpansion (Pall Life Sciences, Port
Washington, NY, USA) systems are examples of this.
Inflated facility size requirements and subsequent capital
investment costs associated with 2D culture scale-up are
challenges facing companies hoping to produce hPSCs on
a commercial scale [44, 45].
Automated, closed-process systems such as the Com-
pacT SelecT (Sartorius AG, Gottingen, Germany), capable
of handling 90 × T175 flasks simultaneously, and the Nunc
Automatic Cell Factory Manipulator (ThermoFisher Sci-
entific), capable of manipulating 4 × 40 layer vessels, may
help increase the throughput of 2D hPSC bioprocess
strategies [46] during expansion and differentiation.
Automated systems allow processing to take place in
smaller, lower clean rooms compared to manual process-
ing. The closed processing offered by automation systems
provides greater process control and reproducibility com-
pared to manual processes [39].
Planar processing platforms will continue to have a
place in commercial hPSC bioprocesses. This is particu-
larly likely for the production of autologous cell therapies
and patient-specific hPSC-derived cells for personalised
medicine drug screening that necessitate a scale-out,
rather than a scale-up approach to bioprocess design [43].
3.2  Three-dimensional culture systems 
for hPSC expansion
There are two main methods of 3D hPSC culture; the use
of suspended microcarriers as adherent surfaces for stem
www.biotechnology-journal.com www.biotecvisions.com
Biotechnology
Journal Biotechnol. J. 2015, 10, 83–95
86 © 2014 The Authors. Biotechnology Journal published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
87
cell growth [47], or growth of hPSCs as suspended aggre-
gates in SUBs [48]. 3D hPSC culture systems allow online
process monitoring, provide greater scalability potential
and reduce facility size requirements when compared to
planar technologies. Bioreactor systems also permit strict
control of conditions during bioprocesses [49]. A chal-
lenge to implementation of 3D culture of hPSCs is expo-
sure of cells to shear forces, which must be tightly con-
trolled as they can impact upon hPSC fate determination
[50, 51]. Development of xeno-free, defined media [52] is
crucial to the robust bioprocessing of hPSCs. The sim-
plicity of such media may reduce costs associated with
hPSC expansion materials by 30–60% [53].
3.2.1  Microcarrier-based systems for hPSC expansion
Microcarriers are small beads or discs, which permit prop-
agation or directed differentiation of hPSCs within a 3D
bioreactor. hPSC studies investigating microcarriers have
recently achieved expansion folds as high as 28-fold over
6 days [54]. Microcarrier-based expansion folds are often
higher than those in 2D expansion studies across similar
timescales [46, 47, 55–57]. Several recently published
reviews include summary tables for SUB-based hPSC
expansion studies (using both microcarrier and aggre-
gate culture strategies [25, 28, 29].
A critical property of microcarriers is their high sur-
face area to volume ratio, on which large populations of
hPSC cells may be cultured in a relatively small vessel,
alleviating the costs associated with expensive media
and supplements necessary for hPSC bioprocessing [28,
56]. Microcarriers are able to support expansion and long-
term self-renewal of hPSCs over multiple passages, prov-
ing the platform’s capability to support production of clin-
ically relevant cell numbers [47]. Microcarrier culture of
hPSCs also results in cell colonies that generally have less
than 10 layers [58]; thus concentration profiles of nutrients
and signalling molecules are less likely to occur than in
aggregate-based cultures.
The common use of microcarrier coatings that contain
animal-derived components, which are unsuitable for use
in the manufacture of cell therapies, is a significant chal-
lenge to culture of hPSCs on microcarriers. Serum-free
and feeder-free microcarrier platforms are available for
hPSC-based processing, although many of these utilise
the microcarrier coating, Matrigel, which is derived from
murine origins [25]. Recombinant human proteins can
now be used as a substitute for animal-derived microcar-
rier coatings in planar and 3D microcarrier cultures [59,
60]. However, such proteins can be difficult to isolate,
expensive to produce, and prone to lot-to-lot variation.
Synthetic substrates, which circumvent consistency
issues associated with recombinant substrates, have
been developed in planar conditions and successfully
applied to microcarrier-based hPSC culture [61–63].
Xeno-free microcarrier coatings utilise polymers to
mimic Matrigel and feeder layer properties in order to
encourage attachment and self-renewal of hPSCs on
microcarriers. Expansion folds on xeno-free microcarriers
comparable to those coated with Matrigel have been
reported [60, 63]. It has been proposed that positively
charged microcarriers can be used to successfully sup-
port hPSC expansion at clinically relevant scales and sim-
ilar cell concentrations and expansion folds to coated
microcarriers were achieved [58]. Methods of xeno-free
hPSC culture represent a regulatory compliant approach
to the production of hPSCs for clinical applications; they
also reduce additional expenses incurred by the use of
supplementary serums. Development of xeno-free micro-
carrier coatings is one area where a quality-by-design
(QbD) approach to product development has allowed elu-
cidation of specific properties of microcarriers that affect
hPSC self-renewal.
Harvesting of cells from microcarriers is usually car-
ried out using enzymatic separation, which can add to
material costs associated with microcarrier-based culture
of hPSCs. Microcarriers coated in thermo-sensitive poly-
mers that allow detachment of seeded cells obviate the
need for dissociation enzymes, although studies in this
area are still in their preliminary phases in this area [64].
Parallel to developing GMP-based hPSC expansion
protocols, research has focused on optimising bioreactor
conditions for dynamic hPSC expansion processes so as
to increase achievable expansion folds and cell concen-
trations. This will help reduce COG associated with man-
ufacture of hPSCs. Controlling the dissolved oxygen levels
has been found to be critical during hPSC culture on
microcarriers in SUBs; 2.5 higher expansion folds and
~85% improvements in maximum cell concentrations
were reported in a hypoxic environment when compared
to uncontrolled conditions [57]. Furthermore, attachment
of hPSCs to microcarriers as single cells can improve
seeding efficiency from 30 to over 80% and reduce dura-
tions associated with microcarrier loading compared to
clump seeding [63].
3.2.2  Aggregate suspension culture of hPSCs
hPSCs can be cultured as suspended aggregates in biore-
actors. When hPSCs are grown as aggregates the rho-
associated protein kinase inhibitor (ROCKi), Y-27632, is
used to protect single cells from dissociation-induced
apoptosis [65]. Each cell aggregate is treated as a de fac-
to colony. Aggregate sizes must be controlled in suspen-
sion bioreactors to prevent differentiation of cells in larg-
er colonies [66–68]. It has been reported that aggregate
culture of stem cells increases the therapeutic potential
and the differentiation efficiency of hPSCs via the sus-
tainment of endogenous signalling within cell colonies
[32]. Aggregate expansion of hPSCs also negates the need
for expensive (and sometimes undefined) components of
substrates upon which hPSCs are cultivated in adherent
cultures [67]. Aggregate culture of hPSCs rely more heav-
ily on the expensive media supplements (such as GFs)
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compared to microcarrier culture [54]. Several groups
have proposed methods of hPSC culture through the use
of cell aggregates with the potential to be scaled up in
order to produce clinically relevant cell numbers [67–69].
Twenty-fivefold expansion has been achieved over 14 days
during aggregate-based hPSC culture [49] and studies
into expansion of hPSCs as aggregates yield similar
expansion-folds when compared to microcarrier systems
[70–72]. Long-term maintenance of hPSCs in aggregates
in dynamic bioreactor conditions over several passages
has also been proven to be feasible [49, 68]. Aggregate-
based hPSC cultivation necessitates frequent manual
interactions in order to control aggregate sizes [28, 71, 73],
which will adversely affect labour costs and the robust-
ness of aggregate-based hPSC bioprocesses.
Agitation rates can be used to successfully modulate
uniform aggregate size in order to improve expansion of
hPSCs as aggregates and reduce cell loss due to shear
forces [53, 68]. This is also the case with microcarrier cul-
tures, where impeller speeds of between 45 and 60 rpm
were found to promote optimal cell population doubling
times [74]. The effects of shear on hPSC self-renewal and
lineage determination is an area of intensifying research,
although currently this is a poorly understood area in
terms of the effect of mechanical strain on hPSC fate
determination [29, 75].
The importance of cell inoculation concentration has
been demonstrated during aggregate culture of hPSCs in
dynamic bioreactor conditions; seeding concentrations of
2–3  × 105 cells/mL were found to maximise viability of
hPSCs [68, 76]. Single cell inoculation has also been esti-
mated to reduce cell losses by up to 60% [68]. Cell concen-
trations of up to 3.4 × 106 hPSCs/mL have been achieved
using dynamic, aggregate-based culture techniques [76].
This represents 1.9-fold improvement over maximum cell
concentrations achieved in planar systems, although it is
significantly lower than the maximum cell concentrations
achieved in xeno-free hPSC cultures performed in micro-
carrier-based systems (6 × 106 cells/mL) [77].
A few aggregate hPSC expansion processes combine
xeno-free conditions with defined media [53, 69, 71].
These investigations represent a valuable effort to remove
media supplements that either introduce the risk of xeno-
geneic material to hPSCs or expose media to lot-to-lot
variability, although early attempts resulted in relatively
modest expansion folds [69].
4  hPSC bioprocessing strategies:
Differentiation
4.1  Planar strategies for hPSC differentiation
Traditional stem cell differentiation protocols were
designed around bench-scale research paradigms and lit-
tle effort was made to incorporate reproducibility and
process robustness into these experiments [78]. Directed
differentiation strategies often involve exposing hPSCs to
a cocktail of morphogens, at specific time-points through-
out the differentiation process [79–82]. Similar to hPSC
expansion, traditional differentiation strategies rely heav-
ily upon the use of xenogeneic materials [83]. Planar dif-
ferentiation protocols, that are free of xenogeneic materi-
al, have been reported [84]. Despite such progress, many
differentiation protocols are inherently variable owing to
the laboratory idiosyncrasies of individual technicians,
thus reliable and robust differentiation processes are still
in their infancy. Timescales and efficiencies also vary sig-
nificantly between experiments even when the same cell
type is targeted for production (Table 3).
The use of small molecules within differentiation pro-
tocols has helped to improve their reproducibility via
reduced use of recombinant growth factors [85, 86]. Sev-
eral groups have created highly simplified protocols,
whilst still improving the efficiency and processing times
of 2D differentiation processes, by replacing growth fac-
tors with small molecules in the preliminary stages of dif-
ferentiation protocols [84, 87, 88]. A protocol with the
specified aim of creating a differentiation process capable
of creating dopaminergic neurons for transplantation in 
T-flasks has been developed [89]. This strategy enabled
the production of cryopreservable dopaminergic neurons
with a high level of efficiency, allowing better control of
time management in within the differentiation process.
This approach is well served to reduce bottlenecks in the
downstream phases of autologous hPSC processes. Fur-
ther advances have proven it is possible to derive pro-
genitor cells, suitable for transplantation as cell therapies
at high efficiencies [90] and in xeno-free and small-mole-
cule free, defined conditions [91]. Negation of the need for
small molecules and growth factors also has the potential
to drastically reduce the cost of differentiation proce-
dures.
4.2  Bioreactor-based systems 
for hPSC differentiation
Concentrated research into bioreactor-based differentia-
tion strategies has stemmed from the need to translate
differentiation from a lab-scale area of research into
processes capable of producing industrially relevant cell
numbers in a reproducible manner. A number of studies
in which hPSCs have been successfully differentiated in
bioreactor conditions have been carried out, either
attached to microcarriers [92] or in the form of cell aggre-
gates [93, 94]. Differentiation strategies developed in 3D
bioreactors, particularly stirred-tank vessels, lend them-
selves to large-scale processes far better than their planar
counterparts as labour-intensive tasks, such as media
exchanges, can be fully automated in such vessels, which
also offer processing advantages such as online environ-
mental monitoring and control. Research carried out on
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SUB-based differentiation of mPSCs suggests that the use
of spinner flasks resulted in a 12-fold reduction of the man
hours spent in the laboratory when compared to planar
techniques [95].
hPSCs can be differentiated towards a number of clin-
ically relevant lineages in SUBs including cardiac [96],
haematopoietic [92], neuronal [77] and hepatocyte-like
[94] (see Table 3 for summary). Bioreactor-based differen-
tiation will be necessary in order to produce certain hPSC-
derived cell products at commercially relevant scales,
however it must be considered that such processes will
only be made more cost-effective by making concurrent
improvements in differentiation efficiencies and through
the reduction of expensive media supplements in such
protocols. Bioreactor-based differentiation would benefit
from the translation of highly efficient protocols demon-
strated in planar systems [88, 91, 97] to SUB systems.
Such protocols have the potential to result in differentia-
tion efficiencies that are higher than those achieved with
SUB-based bioreactors alone. A novel, microparticle-
based approach to morphogen delivery to PSC aggregates
was reported as a method to achieve up to a 12-fold reduc-
tion in morphogen use during bioreactor-based differen-
tiation protocols [98]. Such systems provide a valuable
method by which to reduce material costs associated
with SUB-based hPSC culture.
One question arising from the birth of SUB-based
hPSC differentiation is how a dynamic, controlled envi-
ronment might be harnessed to augment processing
strategies in this area [51]. One of the reasons for the lack
of characterisation with regards to the effects of shear on
hPSCs, is that different dynamic culture systems result in
different shear profiles. Thus, drawing comparisons
across separate studies is difficult [75]. However, scale-
down studies suggest that shear stress during early hPSC
differentiation promotes mesodermal, endothelial and
haematopoietic phenotypes even when the presence of
morphogens promoting these lineages were absent
[99–101]. Interestingly, in early stages of differentiation,
hPSCs lineage determination seems to be insensitive to
the magnitude of shear stress; however in later stages,
progenitor cell activity appears to be more magnitude-
sensitive [100, 102]. Shear forces have been shown to par-
tially negate the need for costly media supplements in
published studies [99, 100]; broadening our knowledge of
the way that shear stress impacts upon hPSC culture
must be seen as an important factor in bioprocess opti-
misation. Hypoxic environments, which can be tightly
controlled within SUBs, have also been shown to enhance
differentiation of hPSCs towards both ectoderm and
mesoderm cell lineages [96, 103].
Novel, microfluidic systems could be a key tool in elu-
cidating the effects of specific environmental parameters
on hPSC propagation and differentiation. Microfluidic
bioreactors provide an ultra-scale down, high throughput
platform by which to study single cells or colonies in
strictly defined conditions [104–107]. The cellular proc -
esses governing hPSC fate are complex and cannot be
attributed to a single given parameter. Microfluidic
devices are well placed, as a low cost development plat-
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Table 3. Key performance characteristics of planar and bioreactor-based differentiation protocols
Derived cell-type Method Time Number of target Reported Max. cell Refs.
(days) cells per input efficiency concentration 
hPSC (ratio) (%) (cells/mL)a)
Cardiomyocyte 2D monolayer 9 ND 64.8 ± 3.3 2.5–5 × 104 [87]
Cardiomyocyte 2D EB formation 60 0.81 10 ± 2 – 22 ± 4 ND [80]
Hepatocytes 2D EB formation ND ND 50 ± 2 1–5 × 104 [81]
Hepatocytes 2D monolayer 14 ND 73 ± 18 ND [82]
Motor neurons 2D monolayer 14 ND 33.6 ± 12 ND [79]
Neural nociceptors 2D monolayer 15 ND 61 ± 2 1 × 104 [88]
Neurons 2D monolayer ~7 ND ND 4.5 × 104 [84]
Dopaminergic neurons 2D monolayer ~28 ND 30 ± 2 ND [89]
Neural progenitor cells 2D monolayer 6 ND 90 ± 1 5 × 104 [91]
Endoderm progenitors 2D monolayer 4 ND 73.2 ± 1.6 1.3 × 105 [90]
Cardiomyocytes 2D EB formation 16–18 70 87 ± 3.4 4.5 -6 × 104 [97]
Cardiomyocytes SUB microcarriers 16 0.33 15.7 ± 3.3 1.36 × 106 [93]
Haematopoietic cells SUB microcarriers 7 4.41 ND ND [92]
Cardiomyocytes SUB cell aggregates 18 23 100% beating 4.3 × 105–5.2 × 105 [96]
aggregates
Hepatocyte-like cells SUB cell aggregates 21 ND 18 ± 7 3–5 × 105 [94]
(HLCs)
ND, no data.
a) In planar studies cell concentrations per mL have been estimated based on cell densities and recommended working volume for vessels used in these studies as
no cell concentrations are provided in studies of this type.
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Figure 1. hPSC bioprocess strategies and their characteristics: (A) Planar processing strategies (top panels) rely on multi-layer vessels. Development of
SUBs for PSC culture and differentiation has allowed development of 3D strategies, which are suitable for large-scale allogeneic bioprocesses (middle pan-
els). Integrated bioprocesses allow hPSC expansion and differentiation to be carried out as a single unit operation in the same bioreactor (bottom panels).
(B) Traditional and integrated autologous iPSC bioprocess strategies: Tradtional planar strategies neccessitate the need for use of well-plates and T-Flasks.
Novel, automated bioreactor systems such as the Ambr system (Sartorius AG) may allow implementation of bioprocess strategies whereby reprogram-
ming, iPSC expansion and differentiation are carried out within a single bioreactor. (C) Segregated and integrated allogeneic bioprocess strategies: Trad-
tional allogneic bioprocess strategies utilise multi-layer, planar technologies. Segregated bioprocessing stratagies make use of separate SUBs for hPSC
expansion and differentiation. Integrated bioprocessing allows hPSC expansion and differentiation to be carried out within a single bioreactor as a single
unit opearation.
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form, to enhance our understanding of how defined
microenvironmental conditions can affect hPSC activity
[108].
The effect of the biochemical properties of microcarri-
ers on hPSC fate determination is poorly understood. It
has also been suggested that the mechanical properties
of microcarriers, such as their stiffness and size can also
be investigated and optimised for specific purposes [27].
Rational design of microcarriers could provide an opti-
mized bioprocess platform with which to manufacture
specific hPSC-derived cell lineages. This would enable
better control of cells’ microenvironment and thus allow
more efficient differentiation processes that do not rely as
heavily on expensive media supplements as current plat-
forms do.
5  Integrated bioprocess design strategies 
for hPSCs
Novel, integrated hPSC bioprocesses, whereby multiple
unit operations are carried out using continuous culture
strategies, are being explored as an alternative to segre-
gated bioprocess strategies. Integrated bioprocesses
negate the need for labour-intensive processes that usu-
ally take place following hPSC expansion such as harvest
and transfer of cells prior to differentiation. Processing
hPSCs in this manner can help to avoid process bottle-
necks and increase throughputs of hPSC product manu-
facture. Additionally, integrated iPSC bioprocess proto-
cols offer greater containment capabilities, reducing the
potential for contamination within the bioprocess. Sever-
al studies in which hPSC expansion and differentiation
are carried out as a single unit operation using continu-
ous culture strategies exist [67, 74, 77]. Figure 1A illus-
trates how these strategies differ from segregated culture
and differentiation of hPSCs. Only a handful of investiga-
tions into this relatively new area of hPSC bioprocess
research have been published and these are summarised
in Table 4.
Early investigations incorporating expansion and dif-
ferentiation focused on overcoming the technical hurdles
of carrying out two different operations in one integrated
process step; as such only modest yields of target cells
were achieved [74]. Recent studies have sought to opti-
mise integrated iPSC bioprocesses via strategies such as
the determination of optimal aggregate size during hPSC
culture and differentiation [67]. Switching feeding
regimes from once to twice per day was found to double
the achievable cell density during the expansion phase of
an integrated bioprocess, although process economic
analysis comparing the two approaches was not offered
[77]. The reported expansion folds and differentiation effi-
ciencies for integrated bioprocesses compare well with
separated systems of a similar nature (Table 4).
To date, no studies have produced an integrated
process for hPSCs from derivation all the way through to
differentiation. This has been achieved with mouse 
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Table 4. Key performance characteristics of studies investigating the integrated expansion and differentiation of hPSCs
Culture Cell type Target Expansion max. Differentiation Reported Process Target cells Xeno-free Refs.
conditions (iPSC/ESC) cell type cell density max. cell differentiation time produced (Y/N)
(cells/mL) (fold density efficiency (%) (days) per input 
expansion) (cells/mL) hPSC
(fold 
expansion)
Microcarrier hiPSC Neural 6.1 × 106 (20) 1.1 × 106 (16.6) 78 ± 4.7 25 333 N [77]
(DE53 progenitor 
Whatman) cells (NPCs)
Microcarrier hESC NPCs 4.3 × 106 (21.3) 1 × 106 (17.7) 83 ± 8.5 23 371 N [77]
(DE53 
Whatman)
Aggregate hESC Definitive ND (5000)a) ND (23.5) > 80% 22 65,000a) N [67]
culture endoderm 
progenitors 
(DEPs)
Microcarrier hESC DEPs 1 × 106 (34–45) 4 × 105 (ND) 84.2 ± 2.3% 12 4 N [74]
(collagen-
coated 
hyclone)
Parameters given for both expansion and differentiation where available. ND = No data given.
a) hESCs underwent four rounds of expansion during this study, as opposed to one round of expansion in other studies shown here. This may contribute to the
 disparity in performance parameters between this study and others shown here. ((Please start this sentence as a new line))
iPSCs (miPSCs) in a SUB [109]. To our knowledge, there
are only two studies exhibiting ‘suspension culture repro-
grammed iPSCs’, both of which deal with miPSCs [109,
110]. Translation of integrated miPSC production tech-
niques described by Baptista et al. [110] to hiPSC pro-
cessing may be particularly useful in the production of
autologous stem cell therapies, where continuous deriva-
tion of large numbers hiPSCs would help reduce the bot-
tlenecks bought about by cellular reprogramming. More-
over, it may provide a ‘black box’ platform to derive,
expand and differentiate a patient’s cells in a single, con-
tained unit that could be installed at point-of-care centres
for relevant disease types. Novel, controlled miniature
bioreactor systems, such as the ambr15 (Sartorius AG),
might offer a suitable platform for autologous hiPSC prod-
uct manufacture, where limited cell numbers are required
and scale-out strategies necessitate alternatives to large-
scale bioreactors (Fig. 1B and 1C).
6  Concluding remarks
The fulfilment of the clinical potential of hPSCs depends
on the development of scalable, robust, GMP-compliant
bioprocesses. Concentrated efforts to develop rigorously
designed bioprocesses with a greater emphasis placed on
QbD will continue to enhance process understanding
with respects to defining critical quality attributes and
identifying key process variables that must be controlled.
hPSC-derived products are subject to strict economic
boundaries owing to the nature of global healthcare sys-
tems. Future work must build upon the promise of works
reviewed in this paper in order to make delivering such
products on budget an achievable goal. Novel approach-
es discussed in this review offer methods to further opti-
mise hPSC bioprocessing platforms.
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